AMYPAD Diagnostic and Patient Management Study: Rationale and design - Université Toulouse III - Paul Sabatier - Toulouse INP Accéder directement au contenu
Article Dans Une Revue Alzheimer's & Dementia : the Journal of the Alzheimer's Association Année : 2018

AMYPAD Diagnostic and Patient Management Study: Rationale and design

Andrew Stephens
  • Fonction : Auteur
Nicola Raffa
  • Fonction : Auteur

Résumé

Introduction Reimbursement of amyloid–positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost‐effectiveness. The Amyloid Imaging to Prevent Alzheimer's Disease–Diagnostic and Patient Management Study (AMYPAD‐DPMS) is designed to fill this gap. Methods AMYPAD‐DPMS is a phase 4, multicenter, prospective, randomized controlled study. Nine hundred patients with subjective cognitive decline plus, mild cognitive impairment, and dementia possibly due to Alzheimer's disease will be randomized to ARM1, amyloid‐PET performed early in the diagnostic workup; ARM2, amyloid‐PET performed after 8 months; and ARM3, amyloid‐PET performed whenever the physician chooses to do so. Endpoints The primary endpoint is the difference between ARM1 and ARM2 in the proportion of patients receiving a very‐high‐confidence etiologic diagnosis after 3 months. Secondary endpoints address diagnosis and diagnostic confidence, diagnostic/therapeutic management, health economics and patient‐related outcomes, and methods for image quantitation. Expected Impacts AMYPAD‐DPMS will supply physicians and health care payers with real‐world data to plan management decisions.
Fichier principal
Vignette du fichier
FRISONi_2019.pdf (1.26 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04605574 , version 1 (07-06-2024)

Licence

Identifiants

Citer

Giovanni B Frisoni, Frederik Barkhof, Daniele Altomare, Johannes Berkhof, Marina Boccardi, et al.. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 2018, 15 (3), pp.388-399. ⟨10.1016/j.jalz.2018.09.003⟩. ⟨hal-04605574⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More